Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012291
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The company’s product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Partnerships 11
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
Licensing Agreements 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Equity Offering 22
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc – Key Competitors 28
Infinity Pharmaceuticals Inc – Key Employees 29
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Strategy And Business Planning 31
Jan 11, 2016: Infinity Provides Key 2016 Goals and Financial Guidance 31
Financial Announcements 32
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 32
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 34
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 37
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 38
Nov 09, 2016: Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results 40
Aug 09, 2016: Infinity Provides Company Update And Reports Second Quarter 2016 Financial Results 42
May 04, 2016: Infinity Provides Company Update And Reports First Quarter 2016 Financial Results 44
Feb 23, 2016: Infinity Provides Company Update and Reports Full-Year 2015 Financial Results 46
Corporate Communications 48
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 48
Jan 04, 2017: Infinity Announces Organizational Changes 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Infinity Pharma Extends Co-Development Agreement With Mundipharma 14
PellePharm Enters into Licensing Agreement with Infinity Pharma 16
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 17
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 19
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 20
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 22
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 23
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 25
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 26
Infinity Pharmaceuticals Inc, Key Competitors 28
Infinity Pharmaceuticals Inc, Key Employees 29
Infinity Pharmaceuticals Inc, Subsidiaries 30

★海外企業調査レポート[Infinity Pharmaceuticals Inc (INFI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報
    Summary Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. …
  • The Jim Pattison Group:企業の戦略・SWOT・財務情報
    The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report Summary The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nordea Private Banking:企業の戦略・SWOT・財務情報
    Nordea Private Banking - Strategy, SWOT and Corporate Finance Report Summary Nordea Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China Foods Ltd:企業の戦略・SWOT・財務分析
    China Foods Ltd - Strategy, SWOT and Corporate Finance Report Summary China Foods Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Vortex Energy Holding AG:電力:M&Aディール及び事業提携情報
    Summary Vortex Energy Holding AG (Vortex Energy) is a provider of renewable energy services. The company's services include development, consulting, financing, planning, implementation, construction, technical management, technical inspection, commercial management, and energy trading services. It a …
  • Impala Platinum Holdings Ltd:企業の戦略・SWOT・財務情報
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Obsidian Energy Ltd (PWT)-石油・ガス分野:企業M&A・提携分析
    Summary Obsidian Energy Ltd (Obsidian) is formerly known as Penn West Petroleum Ltd it is a conventional oil and natural gas producer in Canada. It develops and explores oil and gas properties and related production infrastructure in the Western Canada Sedimentary Basin. Obsidian operates properties …
  • Biotronik SE & Co KG:企業の戦略的SWOT分析
    Biotronik SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mahle GmbH:企業の戦略的SWOT分析
    Mahle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Kolon Industries Inc (120110):企業の財務・戦略的SWOT分析
    Kolon Industries Inc (120110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Dynapac Co., Ltd.:企業の戦略・SWOT・財務情報
    Dynapac Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dynapac Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • Northern Minerals Ltd (GPP):企業の財務・戦略的SWOT分析
    Summary Northern Minerals Ltd (Northern Minerals) formerly known as Greenpower Energy Limited, is a mining, exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explo …
  • Cooperativa Muratori & Cementisti C.M.C di Ravenna:企業の戦略・SWOT・財務分析
    Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report Summary Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Texwinca Holdings Limited:企業の戦略・SWOT・財務分析
    Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • MSC Industrial Direct Co Inc (MSM):企業の財務・戦略的SWOT分析
    MSC Industrial Direct Co Inc (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Trina Solar Co Ltd:企業の戦略的SWOT分析
    Trina Solar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • FortisBC Inc:企業の戦略的SWOT分析
    FortisBC Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • London Stock Exchange Group Plc:企業のM&A・事業提携・投資動向
    London Stock Exchange Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's London Stock Exchange Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Michigan Public Power Agency:企業の戦略的SWOT分析
    Michigan Public Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆